Identification of a novel cancer microbiome signature for predicting prognosis of human breast cancer patients

Mao, Aiqin; Young, Jennifer; Paley, A; Mao, Jianhua; Chang, Hang

doi:10.1007/s12094-021-02725-3

Cited by 18 publications

(21 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The microbiome possesses a large set of possible biomarkers; the different subtypes of breast cancer have different microbiomes that can be distinguished [ 70 , 75 ]. Reports have identified possible markers both at the level of nucleic acids [ 69 , 70 , 72 , 75 ] and at the protein level [ 81 ] in the breast and stool for the detection of the disease. Certain markers are quite promising (ROCs between 0.888 and 0.917).…”

Section: Discussionmentioning

confidence: 99%

“…Multiple microbial compartments undergo oncobiotic transformation during breast cancer, including breast tissue [55,56], milk ducts [57], the inherent microbiome of the breast carcinoma [54,[58][59][60][61][62][63][64][65][66][67][68][69][70][71][72], the distal gut [51,52,[73][74][75][76][77][78][79][80][81][82][83][84][85][86][87][88][89], and the urinary microbiome [54,90]. However, no differences in the microbiome of the nipple [57,69] and the oral microbiome [54] between healthy individuals and breast cancer patients have been detected.…”

Section: Oncobiosis In Breast Cancermentioning

confidence: 99%

“…Antibiotic overdosing, which induces oncobiosis and supports the development of breast cancer, can increase the frequency of disease recurrence [ 29 ]. Components of the intratumoral and tissular microbiome correlate with patient survival [ 70 , 72 ]. Based on the assessment of over 1000 archived breast cancer tissue samples, 46 bacteria were identified as risk factors (including Leptospira , Desulfotalea , Archangium , Dicipivirus , Halosimplex , Spo1virus , Candidatus_Amoebophilus , Roseibium , and Arcticibacter ), while 48 bacteria were identified as favorable factors (including Gordonia , Planktothricoides , Lachnoclostridium , Bafinivirus , Actinomadura , and Methanothermus ) [ 72 ].…”

Section: The Role Of Oncobiosis In Metastasis Formation Survival and ...mentioning

confidence: 99%

“…Based on the assessment of over 1000 archived breast cancer tissue samples, 46 bacteria were identified as risk factors (including Leptospira , Desulfotalea , Archangium , Dicipivirus , Halosimplex , Spo1virus , Candidatus_Amoebophilus , Roseibium , and Arcticibacter ), while 48 bacteria were identified as favorable factors (including Gordonia , Planktothricoides , Lachnoclostridium , Bafinivirus , Actinomadura , and Methanothermus ) [ 72 ]. Mao and colleagues [ 72 ] identified bacterial patterns in breast cancer tissue that strongly correlate with prognosis; poor and good prognosis patients could be separated based on these bacterial patterns (AUC > 0.8). Terrisse et al [ 86 ] demonstrated that stool/fecal transfer of the human microbiome into tumor-bearing mice transformed the properties of the mouse tumors to the human counterpart (e.g., rapidity of progression).…”

Section: The Role Of Oncobiosis In Metastasis Formation Survival and ...mentioning

confidence: 99%

See 3 more Smart Citations

The involvement of oncobiosis and bacterial metabolite signaling in metastasis formation in breast cancer

Kovàcs

Mikó

Ujlaki

et al. 2021

Cancer Metastasis Rev

View full text Add to dashboard Cite

Breast cancer, the most frequent cancer in women, is characterized by pathological changes to the microbiome of breast tissue, the tumor, the gut, and the urinary tract. Changes to the microbiome are determined by the stage, grade, origin (NST/lobular), and receptor status of the tumor. This year is the 50th anniversary of when Hill and colleagues first showed that changes to the gut microbiome can support breast cancer growth, namely that the oncobiome can reactivate excreted estrogens. The currently available human and murine data suggest that oncobiosis is not a cause of breast cancer, but can support its growth. Furthermore, preexisting dysbiosis and the predisposition to cancer are transplantable. The breast’s and breast cancer’s inherent microbiome and the gut microbiome promote breast cancer growth by reactivating estrogens, rearranging cancer cell metabolism, bringing about a more inflammatory microenvironment, and reducing the number of tumor-infiltrating lymphocytes. Furthermore, the gut microbiome can produce cytostatic metabolites, the production of which decreases or blunts breast cancer. The role of oncobiosis in the urinary tract is largely uncharted. Oncobiosis in breast cancer supports invasion, metastasis, and recurrence by supporting cellular movement, epithelial-to-mesenchymal transition, cancer stem cell function, and diapedesis. Finally, the oncobiome can modify the pharmacokinetics of chemotherapeutic drugs. The microbiome provides novel leverage on breast cancer that should be exploited for better management of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Oncobiosis In Breast Cancermentioning

confidence: 99%

Section: The Role Of Oncobiosis In Metastasis Formation Survival and ...mentioning

confidence: 99%

Section: The Role Of Oncobiosis In Metastasis Formation Survival and ...mentioning

confidence: 99%

See 2 more Smart Citations

The involvement of oncobiosis and bacterial metabolite signaling in metastasis formation in breast cancer

Kovàcs

Mikó

Ujlaki

et al. 2021

Cancer Metastasis Rev

View full text Add to dashboard Cite

show abstract

“…In addition to cancer genomic heterogeneity, a significant number of studies have revealed the diversity of the microbiome in cancer and the roles of the microbiome in cancer development and response to therapies[ 15 - 18 ]. We have recently developed a novel cancer microbiome signature for predicting the prognosis of BC patients[ 19 ]. Given the importance of tissue histology, genomics, and microbiome in cancer diagnosis and treatment, efficient and effective integration of these multimodal data is believed to open a new era for precision oncology[ 20 ].…”

Section: Introductionmentioning

confidence: 99%

iCEMIGE: Integration of CEll-morphometrics, MIcrobiome, and GEne biomarker signatures for risk stratification in breast cancers

Mao¹,

Pérez-Losada²,

Abad³

et al. 2022

WJCO

View full text Add to dashboard Cite

BACKGROUND The development of precision medicine is essential for personalized treatment and improved clinical outcome, whereas biomarkers are critical for the success of precision therapies. AIM To investigate whether iCEMIGE (integration of CEll-morphometrics, MIcro biome, and GEne biomarker signatures) improves risk stratification of breast cancer (BC) patients. METHODS We used our recently developed machine learning technique to identify cellular morphometric biomarkers (CMBs) from the whole histological slide images in The Cancer Genome Atlas (TCGA) breast cancer (TCGA-BRCA) cohort. Multivariate Cox regression was used to assess whether cell-morphometrics prognosis score (CMPS) and our previously reported 12-gene expression prognosis score (GEPS) and 15-microbe abundance prognosis score (MAPS) were independent prognostic factors. iCEMIGE was built upon the sparse representation learning technique. The iCEMIGE scoring model performance was measured by the area under the receiver operating characteristic curve compared to CMPS, GEPS, or MAPS alone. Nomogram models were created to predict overall survival (OS) and progress-free survival (PFS) rates at 5- and 10-year in the TCGA-BRCA cohort. RESULTS We identified 39 CMBs that were used to create a CMPS system in BCs. CMPS, GEPS, and MAPS were found to be significantly independently associated with OS. We then established an iCEMIGE scoring system for risk stratification of BC patients. The iGEMIGE score has a significant prognostic value for OS and PFS independent of clinical factors (age, stage, and estrogen and progesterone receptor status) and PAM50-based molecular subtype. Importantly, the iCEMIGE score significantly increased the power to predict OS and PFS compared to CMPS, GEPS, or MAPS alone. CONCLUSION Our study demonstrates a novel and generic artificial intelligence framework for multimodal data integration toward improving prognosis risk stratification of BC patients, which can be extended to other types of cancer.

show abstract

Targeting systemic and gut microbial metabolism in ER+ breast cancer

Heath,

Mogol,

Santaliz Casiano

et al. 2024

Trends in Endocrinology & Metabolism

View full text Add to dashboard Cite

Identification of a novel cancer microbiome signature for predicting prognosis of human breast cancer patients

Cited by 18 publications

References 30 publications

The involvement of oncobiosis and bacterial metabolite signaling in metastasis formation in breast cancer

The involvement of oncobiosis and bacterial metabolite signaling in metastasis formation in breast cancer

iCEMIGE: Integration of CEll-morphometrics, MIcrobiome, and GEne biomarker signatures for risk stratification in breast cancers

Targeting systemic and gut microbial metabolism in ER+ breast cancer

Contact Info

Product

Resources

About